Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

17 Nov 2017
Change (% chg)

$-0.05 (-1.54%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Amgen reports 8.9 pct passive stake in Advaxis as of Aug 1
Tuesday, 2 Aug 2016 

Amgen Inc Reports 8.9 Pct Passive Stake In Advaxis Inc As Of August 1 :Sec filing.  Full Article

Advaxis files for common stock offering
Tuesday, 2 Aug 2016 

Advaxis Inc :Files for common stock offering of up to 3.05 million shares - SEC filing.  Full Article

Advaxis Inc says FDA grants advaxis fast track designation for ADXS-HER2
Thursday, 28 Apr 2016 

Advaxis Inc:Says FDA has granted fast track designation for company's immunotherapy product candidate ADXS-HER2 for patients with newly-diagnosed, non-metastatic, surgically-resectable osteosarcoma.  Full Article

Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma
Tuesday, 1 Dec 2015 

Advaxis, Inc:Says that the European Medicines Agency (EMA) granted Orphan Drug Designation for ADXS-HER2 for the treatment of osteosarcoma.  Full Article

BRIEF-Advaxis Q4 loss per share $1.74

* Advaxis reports business update and third quarter 2017 results